MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion

Eldo T. Verghese, Ruth Drury, Caroline A. Green, Deborah L. Holliday, Xiaomei Lu, Claire Nash, Valerie Speirs, James L. Thorne, Helene H. Thygesen, Alexandre Zougman, Mark A. Hull, Andrew M. Hanby, Thomas A. Hughes

Research output: Contribution to journalArticle

66 Citations (Scopus)
3 Downloads (Pure)

Abstract

Carcinoma-associated fibroblasts (CAFs) influence the behaviour of cancer cells but the roles of microRNAs in this interaction are unknown. We report microRNAs that are differentially expressed between breast normal fibroblasts and CAFs of oestrogen receptor-positive cancers, and explore the influences of one of these, miR-26b, on breast cancer biology. We identified differentially expressed microRNAs by expression profiling of clinical samples and a tissue culture model: miR-26b was the most highly deregulated microRNA. Using qPCR, miR-26b was confirmed as down-regulated in fibroblasts from 15 of 18 further breast cancers. Next, we examined whether manipulation of miR-26b expression changed breast fibroblast behaviour. Reduced miR-26b expression caused fibroblast migration and invasion to increase by up to three-fold in scratch-closure and trans-well assays. Furthermore, in co-culture with MCF7 breast cancer epithelial cells, fibroblasts with reduced miR-26b expression enhanced both MCF7 migration in trans-well assays and MCF7 invasion from three-dimensional spheroids by up to five-fold. Mass spectrometry was used to identify expression changes associated with the reduction of miR-26b expression in fibroblasts. Pathway analyses of differentially expressed proteins revealed that glycolysis/TCA cycle and cytoskeletal regulation by Rho GTPases are downstream of miR-26b. In addition, three novel miR-26b targets were identified (TNKS1BP1, CPSF7, COL12A1) and the expression of each in cancer stroma was shown to be significantly associated with breast cancer recurrence. MiR-26b in breast CAFs is a potent regulator of cancer behaviour in oestrogen receptor-positive cancers, and we have identified key genes and molecular pathways that act downstream of miR-26b in CAFs.

Original languageEnglish
Pages (from-to)388-399
Number of pages12
JournalThe Journal of pathology
Volume231
Issue number3
Early online date9 Oct 2013
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Cell Movement
Fibroblasts
Breast Neoplasms
Carcinoma
MicroRNAs
Neoplasms
Estrogen Receptors
Breast
rho GTP-Binding Proteins
Glycolysis
Coculture Techniques
Mass Spectrometry
Epithelial Cells
Recurrence
Genes

Keywords

  • fibroblast
  • stroma
  • microRNA
  • tumour microenvironment
  • microRNA-26b

Cite this

MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. / Verghese, Eldo T.; Drury, Ruth; Green, Caroline A.; Holliday, Deborah L.; Lu, Xiaomei; Nash, Claire; Speirs, Valerie; Thorne, James L.; Thygesen, Helene H.; Zougman, Alexandre; Hull, Mark A.; Hanby, Andrew M.; Hughes, Thomas A.

In: The Journal of pathology, Vol. 231, No. 3, 11.2013, p. 388-399.

Research output: Contribution to journalArticle

Verghese, ET, Drury, R, Green, CA, Holliday, DL, Lu, X, Nash, C, Speirs, V, Thorne, JL, Thygesen, HH, Zougman, A, Hull, MA, Hanby, AM & Hughes, TA 2013, 'MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion', The Journal of pathology, vol. 231, no. 3, pp. 388-399. https://doi.org/10.1002/path.4248
Verghese, Eldo T. ; Drury, Ruth ; Green, Caroline A. ; Holliday, Deborah L. ; Lu, Xiaomei ; Nash, Claire ; Speirs, Valerie ; Thorne, James L. ; Thygesen, Helene H. ; Zougman, Alexandre ; Hull, Mark A. ; Hanby, Andrew M. ; Hughes, Thomas A. / MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. In: The Journal of pathology. 2013 ; Vol. 231, No. 3. pp. 388-399.
@article{6b1de5149aee4260af06d61f2a042229,
title = "MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion",
abstract = "Carcinoma-associated fibroblasts (CAFs) influence the behaviour of cancer cells but the roles of microRNAs in this interaction are unknown. We report microRNAs that are differentially expressed between breast normal fibroblasts and CAFs of oestrogen receptor-positive cancers, and explore the influences of one of these, miR-26b, on breast cancer biology. We identified differentially expressed microRNAs by expression profiling of clinical samples and a tissue culture model: miR-26b was the most highly deregulated microRNA. Using qPCR, miR-26b was confirmed as down-regulated in fibroblasts from 15 of 18 further breast cancers. Next, we examined whether manipulation of miR-26b expression changed breast fibroblast behaviour. Reduced miR-26b expression caused fibroblast migration and invasion to increase by up to three-fold in scratch-closure and trans-well assays. Furthermore, in co-culture with MCF7 breast cancer epithelial cells, fibroblasts with reduced miR-26b expression enhanced both MCF7 migration in trans-well assays and MCF7 invasion from three-dimensional spheroids by up to five-fold. Mass spectrometry was used to identify expression changes associated with the reduction of miR-26b expression in fibroblasts. Pathway analyses of differentially expressed proteins revealed that glycolysis/TCA cycle and cytoskeletal regulation by Rho GTPases are downstream of miR-26b. In addition, three novel miR-26b targets were identified (TNKS1BP1, CPSF7, COL12A1) and the expression of each in cancer stroma was shown to be significantly associated with breast cancer recurrence. MiR-26b in breast CAFs is a potent regulator of cancer behaviour in oestrogen receptor-positive cancers, and we have identified key genes and molecular pathways that act downstream of miR-26b in CAFs.",
keywords = "fibroblast, stroma, microRNA, tumour microenvironment, microRNA-26b",
author = "Verghese, {Eldo T.} and Ruth Drury and Green, {Caroline A.} and Holliday, {Deborah L.} and Xiaomei Lu and Claire Nash and Valerie Speirs and Thorne, {James L.} and Thygesen, {Helene H.} and Alexandre Zougman and Hull, {Mark A.} and Hanby, {Andrew M.} and Hughes, {Thomas A.}",
note = "This work was supported by the Medical Research Council (ETV), Breast Cancer Campaign (ETV, TAH, VS), Breast Cancer Research Action Group (TAH), Cancer Research UK (HHT, ref C37059/A11941), The Pathological Society UK (ETV), Yorkshire Cancer Research (LMD platform), University of Leeds (CG), and Leeds Institute of Molecular Medicine (CN). We thank Georgia Mavria (University of Leeds), Sean Lawler (Harvard Medical School), and Eric Sahai and Steven Hooper (CR‐UK LRI) for technical advice.",
year = "2013",
month = "11",
doi = "10.1002/path.4248",
language = "English",
volume = "231",
pages = "388--399",
journal = "The Journal of pathology",
issn = "0022-3417",
publisher = "Wiley",
number = "3",

}

TY - JOUR

T1 - MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion

AU - Verghese, Eldo T.

AU - Drury, Ruth

AU - Green, Caroline A.

AU - Holliday, Deborah L.

AU - Lu, Xiaomei

AU - Nash, Claire

AU - Speirs, Valerie

AU - Thorne, James L.

AU - Thygesen, Helene H.

AU - Zougman, Alexandre

AU - Hull, Mark A.

AU - Hanby, Andrew M.

AU - Hughes, Thomas A.

N1 - This work was supported by the Medical Research Council (ETV), Breast Cancer Campaign (ETV, TAH, VS), Breast Cancer Research Action Group (TAH), Cancer Research UK (HHT, ref C37059/A11941), The Pathological Society UK (ETV), Yorkshire Cancer Research (LMD platform), University of Leeds (CG), and Leeds Institute of Molecular Medicine (CN). We thank Georgia Mavria (University of Leeds), Sean Lawler (Harvard Medical School), and Eric Sahai and Steven Hooper (CR‐UK LRI) for technical advice.

PY - 2013/11

Y1 - 2013/11

N2 - Carcinoma-associated fibroblasts (CAFs) influence the behaviour of cancer cells but the roles of microRNAs in this interaction are unknown. We report microRNAs that are differentially expressed between breast normal fibroblasts and CAFs of oestrogen receptor-positive cancers, and explore the influences of one of these, miR-26b, on breast cancer biology. We identified differentially expressed microRNAs by expression profiling of clinical samples and a tissue culture model: miR-26b was the most highly deregulated microRNA. Using qPCR, miR-26b was confirmed as down-regulated in fibroblasts from 15 of 18 further breast cancers. Next, we examined whether manipulation of miR-26b expression changed breast fibroblast behaviour. Reduced miR-26b expression caused fibroblast migration and invasion to increase by up to three-fold in scratch-closure and trans-well assays. Furthermore, in co-culture with MCF7 breast cancer epithelial cells, fibroblasts with reduced miR-26b expression enhanced both MCF7 migration in trans-well assays and MCF7 invasion from three-dimensional spheroids by up to five-fold. Mass spectrometry was used to identify expression changes associated with the reduction of miR-26b expression in fibroblasts. Pathway analyses of differentially expressed proteins revealed that glycolysis/TCA cycle and cytoskeletal regulation by Rho GTPases are downstream of miR-26b. In addition, three novel miR-26b targets were identified (TNKS1BP1, CPSF7, COL12A1) and the expression of each in cancer stroma was shown to be significantly associated with breast cancer recurrence. MiR-26b in breast CAFs is a potent regulator of cancer behaviour in oestrogen receptor-positive cancers, and we have identified key genes and molecular pathways that act downstream of miR-26b in CAFs.

AB - Carcinoma-associated fibroblasts (CAFs) influence the behaviour of cancer cells but the roles of microRNAs in this interaction are unknown. We report microRNAs that are differentially expressed between breast normal fibroblasts and CAFs of oestrogen receptor-positive cancers, and explore the influences of one of these, miR-26b, on breast cancer biology. We identified differentially expressed microRNAs by expression profiling of clinical samples and a tissue culture model: miR-26b was the most highly deregulated microRNA. Using qPCR, miR-26b was confirmed as down-regulated in fibroblasts from 15 of 18 further breast cancers. Next, we examined whether manipulation of miR-26b expression changed breast fibroblast behaviour. Reduced miR-26b expression caused fibroblast migration and invasion to increase by up to three-fold in scratch-closure and trans-well assays. Furthermore, in co-culture with MCF7 breast cancer epithelial cells, fibroblasts with reduced miR-26b expression enhanced both MCF7 migration in trans-well assays and MCF7 invasion from three-dimensional spheroids by up to five-fold. Mass spectrometry was used to identify expression changes associated with the reduction of miR-26b expression in fibroblasts. Pathway analyses of differentially expressed proteins revealed that glycolysis/TCA cycle and cytoskeletal regulation by Rho GTPases are downstream of miR-26b. In addition, three novel miR-26b targets were identified (TNKS1BP1, CPSF7, COL12A1) and the expression of each in cancer stroma was shown to be significantly associated with breast cancer recurrence. MiR-26b in breast CAFs is a potent regulator of cancer behaviour in oestrogen receptor-positive cancers, and we have identified key genes and molecular pathways that act downstream of miR-26b in CAFs.

KW - fibroblast

KW - stroma

KW - microRNA

KW - tumour microenvironment

KW - microRNA-26b

U2 - 10.1002/path.4248

DO - 10.1002/path.4248

M3 - Article

VL - 231

SP - 388

EP - 399

JO - The Journal of pathology

JF - The Journal of pathology

SN - 0022-3417

IS - 3

ER -